Acrivon Therapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the quarter, the company reported net loss was USD 8.929 million compared to USD 4.343 million a year ago. Basic loss per share from continuing operations was USD 0.80 compared to USD 2.45 a year ago. Diluted loss per share from continuing operations was USD 0.80 compared to USD 2.45 a year ago.

For the full year, the company reported net loss was USD 31.17 million compared to USD 16.24 million a year ago. Basic loss per share from continuing operations was USD 7.56 compared to USD 9.32 a year ago. Diluted loss per share from continuing operations was USD 7.56 compared to USD 9.32 a year ago.